Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy
Open Access
- 14 August 2026
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (33)
Abstract
Pulmonary large-cell neuroendocrine carcinoma (LCNEC) is a rare yet highly aggressive subtype of non-small cell lung carcinoma (NSCLC) with limited therapeutic options. We conduct a comprehensive proteogenomic analysis of LCNEC using tumors and paired normal adjacent tissues from 107 patients (81 pure LCNEC and 26 combined LCNEC). APOBEC mutational signatures strongly correlate processes of tumor initiation and immune suppression, and KEAP1 mutations correlate with metabolic reprogramming in LCNEC combined with NSCLC. A conflicting relationship is observed between neuroendocrine and immune phenotypes. We identify three LCNEC subtypes with unique prognosis features, microenvironment dysregulation, genetic alterations, and potential therapeutic targets. Interleukin-33 (IL-33) emerges as a critical therapeutic biomarker associated with enhanced T cell infiltration and antitumor activity. We further optimize recombinant IL-33 (rIL33) with site-directed mutagenesis and develop PEGylated rIL33, demonstrating its prolonged circulation time in cynomolgus monkeys and superior immune agonist activity in mouse models. Overall, this study offers insights into LCNEC biology and provides promising innovative immunoagonist therapy strategies for lung cancer.Keywords
Funding Information
- National Natural Science Foundation of China (82430053)
- National Natural Science Foundation of China (82125001)
- National Natural Science Foundation of China (82471347)
- National Natural Science Foundation of China (82201948)
- National Natural Science Foundation of China (82173393)
- Science and Technology Commission of Shanghai Municipality (24SF1904500)
- Innovation Program of Shanghai Municipal Education Commission (2023ZKZD33)
- Shanghai Pulmonary Hospital (TJ-FK-YXJC003)
- Shanghai Pulmonary Hospital (LYRC202402)
- Shanghai Pulmonary Hospital (FKLY20004)
- Shanghai Pulmonary Hospital (FKYQ2308)
This publication has 101 references indexed in Scilit:
- Targeting the Notch signaling pathway and the Notch ligand, DLL3, in small cell lung cancerBiomedicine & Pharmacotherapy, 2023
- The proteogenomic subtypes of acute myeloid leukemiaCancer Cell, 2022
- Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinomaCancer Cell, 2021
- Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2‐mutant lung cancerInternational Journal of Cancer, 2018
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerCancer Cell, 2018
- Comprehensive Characterization of Cancer Driver Genes and MutationsCell, 2018
- The Human Transcription FactorsCell, 2018
- Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined CancerCell, 2017
- mTORC1-Dependent Metabolic Reprogramming Underlies Escape from Glycolysis Addiction in Cancer CellsCancer Cell, 2016
- ImmPort: disseminating data to the public for the future of immunologyImmunologic Research, 2014